Tuesday, April 30, 2024
Home Biotech News Stem Cells Page 3

Stem Cells

    Featured posts
    Organicell

    Organicell (BPSR) a Triple Since Easter.

    Infections Editor / Curator -
    Slowly she turns, step-by-step. $20 million gain in market value. Spurred by FDA Emergency IND's. RELATED: Adding Organicell (BPSR)...

    Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...

    Stem Cells Editor / Curator -
    Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).   Citius Announces Pre-IND Submission to FDA Under the Coronavirus...

    ‘Amazing potential.’ UM doctor to start stem cell trial for coronavirus patients (Miami Herald)

    CoronaVirus Editor / Curator -
    BY BEN CONARCK APRIL 16, 2020 A team of doctors at the University of Miami won emergency federal approval...

    FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!

    Stem Cells Editor / Curator -
    FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome.
    123Page 3 of 3

    Latest article

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    2024 Watch List Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

    GeoVax (GOVX) Launches Vaccine Manufacturing System.

    2024 Watch List Editor / Curator -
    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.